Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mercaptopurine→

Mercaptopurine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
50-44-2
Molecular formula
C5H4N4S
Molecular weight
152.18 g/mol
Drug class
Purine antimetabolitethiopurine immunosuppressant and antineoplastic agent
Mechanism of action
Converted intracellularly to thioguanine nucleotides and other active metabolites that interfere with purine nucleotide synthesis and incorporation into DNA and RNA, suppressing proliferation of rapidly dividing lymphoid cells.
Indications / reported uses
  • Treatment of acute lymphoblastic leukaemia (ALL) as part of combination chemotherapy, including maintenance regimens; dose and use are specialist-directed and depend on TPMT/NUDT15 status and blood-count monitoring

Sources: US DailyMed — Mercaptopurine tablets/oral suspension · NLM MeSH — Mercaptopurine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mercaptopurine Environmental Risk Assessment (ERA) (the Mercaptopurine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.